Latest news
LCT Gains Ground in EGFR-Mutated NSCLC - OncLiveOncLive · Fri, 07 Aug 2026 14:05:45 GMTRevolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress - GlobeNewswireGlobeNewswire · Wed, 05 Aug 2026 20:02:00 GMTEGFR Amplification in EGFR-Mutated NSCLC: Critical Risk Marker - OncodailyOncodaily · Wed, 05 Aug 2026 14:17:49 GMTIn Squamous NSCLC, Cemiplimab Data Pulled the Room Away From Dual Checkpoint Blockade - Targeted OncologyTargeted Oncology · Tue, 04 Aug 2026 17:39:36 GMT89 Experts Map Key Gray Zones in Non-Metastatic NSCLC - OncodailyOncodaily · Sat, 01 Aug 2026 16:55:11 GMTTurja Chakrabarti: Discussing CTLA-4 Blockade in Metastatic NSCLC at 27th Annual International Lung Cancer Congress - OncodailyOncodaily · Thu, 30 Jul 2026 07:00:00 GMTImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer - ImmunityBioImmunityBio · Wed, 29 Jul 2026 07:00:00 GMTReal-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience - Oncology CentralOncology Central · Mon, 27 Jul 2026 07:00:00 GMT